Spinal Cord Stimulator: Success Rates, Risks and Horror Stories
Spinal cord stimulation can reduce refractory nerve pain, but it is implanted hardware with real failure modes. Here are the success rates, the complications behind the horror stories, costs, and the trial that predicts benefit.
Analyzed Article
This fact-check analysis pertains to a specific external article.
Title: Chronic Pain health topic ( Read original article )
Source: U.S. National Library of Medicine
Claim-by-Claim Ledger
| ID | Claim | Risk | Verdict | Evidence | Notes |
|---|---|---|---|---|---|
| C1 | Spinal cord stimulation is recommended only for chronic neuropathic pain that has not responded to conventional medical management. | medium | supported | V1 | Matches NICE technology appraisal criteria. |
| C2 | A temporary trial period is used before permanent implantation to test whether stimulation meaningfully reduces pain. | low | supported | V1 | Trial-then-implant is the standard pathway. |
| C3 | Hardware complications such as lead migration, infection, and need for revision surgery are the most common causes of poor long-term outcomes. | high | partial | V1, V2 | Complication profiles are well documented; rates vary by device, center, and follow-up length. |
What a spinal cord stimulator is
A spinal cord stimulator (SCS) is an implanted device: thin leads placed in the epidural space deliver electrical pulses to the spinal cord, altering how pain signals reach the brain, powered by a battery implanted under the skin. It is reserved for chronic neuropathic pain that has not responded to conventional medical management, such as persistent radicular pain after spine surgery or complex regional pain syndrome [V1][V2]. It manages pain; it does not treat the underlying structural problem.
Key numbers
- 50%: the pain-reduction threshold usually required to call a trial successful [V1].
- ~1–2 weeks: typical temporary trial duration before permanent implant.
- 6–8 weeks: activity restrictions after implantation while leads scar into place.
- Years, not forever: benefit commonly attenuates over time; revisions are common [V2].
The two-stage pathway
Stage 1 — Trial. Temporary leads are placed percutaneously and connected to an external generator. You keep a pain and function diary for several days to two weeks. A trial is considered positive when pain drops by around half and function or sleep improves [V1].
Stage 2 — Implant. If the trial succeeds, permanent leads and a battery are implanted, usually under sedation or general anesthesia, as a day-case or overnight procedure. Programming is refined over subsequent visits.
Candidates are normally also screened psychologically, because untreated depression, unaddressed substance use, or unrealistic expectations predict poor outcomes [V1].
Honest look at the failure modes
| Problem | What happens | Typical response |
|---|---|---|
| Lead migration | Coverage shifts, pain returns | Reprogramming or revision surgery |
| Infection | Wound infection or pocket infection | Antibiotics; often device explant |
| Loss of efficacy | Benefit fades over months to years | Reprogramming, new waveform, or explant |
| Hardware discomfort | Battery-site pain, tethering | Repositioning |
| Imaging limits | MRI conditional or restricted | Device-specific protocols |
These are what most “horror stories” describe. They are real, documented, and the reason the therapy is positioned as a late-line option after conservative and interventional care have been exhausted [V1][V2].
Who tends to do well
Best results cluster in patients with clearly neuropathic, limb-dominant pain, a positive trial, realistic goals, no untreated psychiatric or substance-use problems, and an active rehabilitation plan alongside the device [V1][S1]. Widespread nociplastic pain, axial-only back pain, and unresolved structural pathology respond poorly.
Questions worth asking before consenting
- What is my specific diagnosis, and is it neuropathic?
- What percentage of your trials convert to implants, and what is your infection and revision rate?
- Which device and waveform, and what are its MRI limitations?
- What is the explant plan if it stops helping?
- What is the total out-of-pocket cost, in writing?
Related reading: spinal cord stimulator cost, nerve block injections, and chronic pain management.
Frequently asked questions
What is the success rate of a spinal cord stimulator?
Among patients who pass a trial, roughly half to two-thirds report at least 50% pain reduction in the first year, and benefit tends to decline over several years. Success depends heavily on patient selection, diagnosis, device type, and the quality of the trial.
Why are there so many spinal cord stimulator horror stories?
Because failures are visible and specific: lead migration causing loss of coverage, infection requiring explant, painful battery pockets, unwanted stimulation, MRI restrictions, and revision surgeries. These are hardware and selection problems rather than proof that the therapy never works.
What can’t you do with a spinal cord stimulator?
Restrictions include heavy lifting, twisting, and reaching overhead during the first 6 to 8 weeks, plus lifelong caution with diathermy, some MRI protocols, therapeutic ultrasound over the device, and certain security or electromagnetic environments. Always follow the manufacturer’s labeling.
How soon can I drive after spinal cord stimulator surgery?
Most surgeons advise not driving while stimulation is switched on, and not driving at all for roughly one to two weeks after implantation, longer if you are taking sedating medication. Follow the specific instructions from your implanting physician.
How much does a spinal cord stimulator cost?
Total costs include the trial, implant surgery, device, facility, and follow-up programming, and typically run into tens of thousands of dollars in the United States before insurance. Medicare and most commercial plans cover it for approved indications with prior authorization.
Disclaimer: This article is for informational and educational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed healthcare professional for personal medical decisions.
References
- [V1] National Institute for Health and Care Excellence. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin (TA159). NICE Guidance. 2008. Source . Accessed 2026-08-03.
- [V2] Dydyk AM, Conermann T. Chronic Pain. StatPearls, NCBI Bookshelf. 2026. Source . Accessed 2026-08-03.
- [S1] U.S. National Library of Medicine. Chronic Pain health topic. MedlinePlus. 2026. Source . Accessed 2026-08-03.
Editorial Notes
Educational review only. This content is not personalized medical advice, diagnosis, or treatment.
Explore More In This Topic
Looking for additional coverage in this category? Browse all Procedures fact checks.